Belimumab reduces aPL titers in primary triple-positive APS patients (144), and an open-label, prospective phase II trial evaluating its use for refractory or non-standard APS manifestations is currently ongoing (145). The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.